EXELIXIS, INC. 13D

Farallon Capital Management and affiliated persons filed a joint Schedule 13D on August 14, 2026, but this exhibit does not disclose stake size or explicit intentions.

This exhibit is a joint acquisition statement for a Schedule 13D filed on August 14, 2026 by Farallon Capital Management, L.L.C. and various affiliated individuals, confirming that the Schedule 13D and all future amendments are being filed on a joint basis; however, this document alone does not provide the size of the stake, any change in ownership, or specific Item 4 intentions, so no conclusions can be drawn about stake size, value, or activist plans from this excerpt.

Filing Facts

CIK

939767

Ticker

EXEL

Form

13D

Source Type

fda

Accession

0000908834-26-000419

Alert Tier

6